Melanotan I

Dosing from the Literature

Published for skin: the 16 mg implant every 2 months, the approved dose for adults with erythropoietic protoporphyria, a rare sun sensitivity (Scenesse label); and 10 daily injections of 0.08–0.21 mg/kg, in early studies in volunteers (Minder et al., 2017). Not published: a trial of the gray-market vials tanners inject.

The approved dose below is the Scenesse 16 mg controlled-release implant (Scenesse label). The other rows are investigational implant regimens, early injection studies in volunteers, and what user forums describe; none is an approved regimen.

What It Is

Melanotan I — generic name afamelanotide, originally coded CUV1647, marketed as Scenesse — is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) (Scenesse label). It is a linear 13-amino-acid peptide (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂; Scenesse label) differing from native α-MSH at positions 4 and 7, where norleucine replaces methionine and D-phenylalanine replaces L-phenylalanine (Haylett et al., 2011). Its activity and stability are higher than the natural hormone’s (Minder et al., 2017), and because serum and proteolytic enzymes do not break it down at once, it binds its receptor longer (EU label). Molecular weight is 1,646.85 Da (Scenesse label). The compound is alternatively abbreviated NDP-α-MSH in the mechanistic literature — "[Nle⁴,D-Phe⁷]-α-MSH."

Afamelanotide was synthesized in 1980 by Mac Hadley, Victor Hruby, and colleagues at the University of Arizona College of Pharmacy. The same group went on to design Melanotan II (a cyclic heptapeptide with pan-melanocortin activity) and, through Palatin Technologies, bremelanotide / PT-141 (approved in 2019 for hypoactive sexual desire disorder). Afamelanotide is the MC1R-selective member of this family — its receptor profile heavily favors MC1R (the receptor that controls skin pigment) activation in cutaneous melanocytes, with much weaker activity at the central MC3R (a melanocortin receptor for energy balance)/MC4R (the receptor that controls appetite) circuits responsible for MT-II's sexual-arousal and appetite effects.

The approved formulation is a bioresorbable poly-D,L-lactide-co-glycolide (PLGA) implant, 1.7 cm long by 1.5 mm diameter, containing 16 mg of afamelanotide. The implant is placed subcutaneously above the supra-iliac crest by a trained health care professional every two months (Scenesse label); the EU label times the implants before and during periods of increased sunlight (EU label). The implant slowly releases afamelanotide over approximately 48–72 hours; the peptide then distributes systemically and drives melanogenesis for the following ~60 days via the melanocytes it has already primed. This controlled-release PK is critical to the safety envelope: rapid injectable bolus dosing (the off-label research-peptide pattern) produces pharmacokinetics fundamentally different from the approved product.

Afamelanotide received its first national approval from the Italian Medicines Agency (AIFA) in 2010 for EPP under a compassionate-use framework. The European Medicines Agency granted a centralized authorization under "exceptional circumstances" in December 2014 (EU/1/14/969), citing the rarity of EPP and the compound's prior compassionate-use data. The US FDA approved Scenesse on October 8, 2019 (NDA 210797) — the first melanocortin agonist approved in the United States for any photoprotective indication. Australia's TGA (2020) and additional national approvals across Europe, Switzerland, and the Middle East followed.

CLINUVEL Pharmaceuticals (ASX: CUV; NASDAQ ADR: CLVLY), headquartered in Melbourne with operations in Europe, developed the product and holds the global rights. Beyond EPP, CLINUVEL has advanced afamelanotide into Phase II/III trials for vitiligo (in combination with narrow-band UVB phototherapy), variegate porphyria, and xeroderma pigmentosum, and into Phase II for hypopigmented skin conditions and post-ischemic stroke neuroprotection (via MC1R's documented cerebrovascular effects).

Mechanism of Action

Afamelanotide is a melanocortin receptor agonist that binds predominantly to MC1R (Scenesse label), with higher activity and stability than natural α-MSH (Minder et al., 2017). MC1R signaling increases melanin synthesis, induces antioxidant activity, enhances DNA repair and modulates inflammation (Minder et al., 2017).

• MC1R binding and cAMP signaling — Afamelanotide binds predominantly to MC1R, and it binds longer than α-MSH, partly because serum and proteolytic enzymes do not break it down at once (EU label). In human melanocytes, α-MSH and ACTH bind MC1R and activate the cAMP pathway that UV-induced tanning requires (Abdel-Malek et al., 2008).
• Tyrosinase activation — In cultured human melanocytes, α-MSH raised cAMP, tyrosinase activity and proliferation through MC1R, in line with its binding affinity for the receptor (Suzuki et al., 1996).
• Eumelanin-selective pigment shift — Acting through MC1R, α-MSH shifts melanin synthesis toward black eumelanin, which is photoprotective, and away from red phaeomelanin, which can generate free radicals under UV (Valverde et al., 1995); afamelanotide increases eumelanin in the skin (Scenesse label). MC1R variants were found in over 80% of people with red hair or fair skin that tans poorly (Valverde et al., 1995), and three of them (R151C, R160W, D294H) are strongly associated with red hair and increased melanoma susceptibility (Abdel-Malek et al., 2008). In two trials in volunteers, neither MC1R variants nor fair skin reduced the rise in pigmentation afamelanotide produced (Minder et al., 2017).
• Nucleotide excision repair enhancement — In normal human melanocytes in vitro, α-MSH itself (not afamelanotide) reduced UVB-induced DNA damage, measured as cyclobutane pyrimidine dimers, and the cell death that follows; the effect appeared to work through nucleotide excision repair, since α-MSH did not protect repair-deficient fibroblasts, and not through melanin filtering or synthesis (Böhm et al., 2005). Melanocortins enhance repair of DNA photoproducts independently of pigmentation (Abdel-Malek et al., 2008).
• Oxidative stress attenuation — In human melanocytes, melanocortins reduce the generation of hydrogen peroxide and inhibit UV-induced apoptosis (Abdel-Malek et al., 2008). The EU label adds that eumelanin filters UV and visible light and scavenges free radicals (EU label).
• Anti-inflammatory effects — MC1R signaling also modulates inflammation, a review notes (Minder et al., 2017).
• Stroke (investigational) — CLINUVEL’s single-arm, open-label Phase IIa study gave afamelanotide to 6 adults after an acute arterial ischemic stroke, to assess its safety and whether it affected the brain tissue at risk through blood flow, oxygen supply and swelling (ClinicalTrials.gov NCT04962503).
• Pharmacokinetics of the implant — Most of the dose is released within 48 hours and over 90% by day 5, the half-life is about 30 minutes, and plasma levels were below quantitation by day 10 in most studies (EU label). In 12 healthy adults given one implant, levels peaked at a median of 36 hours (mean peak 3.7 ng/mL), the apparent half-life from the implant was about 15 hours, and 9 of the 12 had their last measurable level at 96 hours (Scenesse label). In 5 patients with solar urticaria given one implant, melanin density rose by day 7, peaked at day 15 and was still raised at day 60 (Haylett et al., 2011).
• MC1R selectivity — Afamelanotide is a linear 13-amino-acid analog of α-MSH that binds predominantly to MC1R (Scenesse label).

What the Research Shows

Afamelanotide’s core evidence is two randomized, double-blind, placebo-controlled Phase 3 trials in 168 adults with erythropoietic protoporphyria, funded by Clinuvel and others (Langendonk et al., 2015); the FDA label’s efficacy data come from these two trials (Scenesse label). Smaller studies have tested it in vitiligo (Lim et al., 2015) and solar urticaria (Haylett et al., 2011).

• EPP pivotal trials — Langendonk et al., NEJM 2015 (PMID 26132941) — Two parallel randomized, placebo-controlled, double-blind trials enrolled 168 adults with EPP - 74 in the European Union trial and 94 in the United States trial - with the 16 mg implant every 60 days. The primary end point was pain-free time in direct sunlight, between 10 a.m. and 3 p.m. in the European trial and between 10 a.m. and 6 p.m. in the US trial. After nine months the European median was 6.0 hours against 0.8 on placebo (P = 0.005); after six months the US median was 69.4 hours against 40.8 (P = 0.04). Both trials met the primary end point.
• Biddolph 2020 observational disease registry — Analysis of EU Scenesse disease registry showed sustained benefit with repeated dosing over multiple years, with no new safety signals beyond those seen in the pivotal trials.
• Vitiligo randomized trial — Lim et al., JAMA Dermatology 2015 (PMID 25230094) — In 55 adults with nonsegmental vitiligo (Fitzpatrick skin types III–VI), afamelanotide implants added to narrowband UV-B phototherapy gave faster and greater repigmentation than NB-UVB alone: 48.6% vs 33.3% at day 168, with the clearer response in skin types IV–VI.
• Vitiligo case series — Grimes et al., JAMA Dermatology 2013 (PMID 23407924) — An earlier, uncontrolled report of 4 patients with generalized vitiligo on NB-UVB three times weekly plus four monthly 16 mg implants: the authors report faster and deeper repigmentation in each case, and all 4 developed diffuse hyperpigmentation.
• Xeroderma pigmentosum Phase IIa — Two small open-label CLINUVEL studies (CUV152, CUV156) in adults with XP (genetic nucleotide-excision-repair deficiency with severe UV sensitivity) give afamelanotide every two weeks for twelve weeks; ClinicalTrials.gov lists both as status unknown, with no results posted (NCT05370235; NCT05159752).
• Solar urticaria — Case series and small trials in idiopathic solar urticaria; afamelanotide reduced urticarial responses to UVA/UVB provocation.
• Polymorphous light eruption (PLE) — Small clinical studies show reduction in PLE symptom frequency and severity during sun-exposure seasons.
• Stroke Phase IIa (CUV801) — CLINUVEL’s open-label proof-of-concept study in acute arterial ischemic stroke finished in February 2022 with 6 patients and no control group. Its posted results report changes in infarct volume; one patient had serious adverse events (hemorrhagic transformation of the stroke and a cerebrovascular accident), and one died (ClinicalTrials.gov NCT04962503).
• DNA repair / photoprotection mechanism work (Böhm et al., J Biol Chem 2005; PMID 15569680) — Foundational mechanistic paper showing α-MSH protects human melanocytes from UV-induced apoptosis (programmed cell death) and DNA damage via nucleotide-excision-repair enhancement. Underpins the photoprotective rationale beyond pigment.
• Receptor pharmacology (Abdel-Malek et al., Photochem Photobiol 2008; PMID 18282187) — MC1R biology review establishing the receptor's role in the UV response of human melanocytes and the translational rationale for MC1R-targeted photoprotection.

Human Data

Key human trials of afamelanotide:

• European EPP trial (Langendonk NEJM 2015; PMID 26132941) — Multicentre double-blind placebo-controlled trial; N=74; 16 mg implant every 60 days over 270 days. Median pain-free time in direct sunlight between 10 a.m. and 3 p.m. was 6.0 hours against 0.8 on placebo (P = 0.005).
• US EPP trial (Langendonk NEJM 2015) — Parallel US trial; N=94; same implant every 60 days. Median pain-free time in direct sunlight between 10 a.m. and 6 p.m. after six months was 69.4 hours against 40.8 on placebo (P = 0.04). It formed part of the basis of FDA NDA 210797.
• EU Scenesse disease registry (2014–2025) — Post-authorization observational registry documenting sustained benefit and real-world safety across repeat-implant cycles in EPP.
• Lim 2015 vitiligo trial (JAMA Dermatology) — Afamelanotide plus NB-UVB superior to NB-UVB alone for repigmentation in generalized vitiligo (Lim et al., 2015; PMID 25230094).
• Grimes 2013 vitiligo case series — Four uncontrolled patients on NB-UVB plus monthly implants, all of whom repigmented (Grimes et al., 2013; PMID 23407924); it came before the randomized trial, which found the response clearer in Fitzpatrick IV–VI skin (Lim et al., 2015).
• CUV152 and CUV156 xeroderma pigmentosum Phase IIa — Two open-label studies, each planning about 6 adults; ClinicalTrials.gov lists their status as unknown, with no results posted (NCT05370235; NCT05159752).
• Solar urticaria pilot (Haylett et al., 2011; PMID 20969564) — In 5 patients given one 16 mg implant, the weal area after light testing fell at 60 days (P = 0.049), and the minimum dose of light needed to raise a weal more than doubled, short of significance (P = 0.058).
• CUV801 acute stroke Phase II — Proof-of-concept trial in the cerebrovascular indication.
• CUV047 and related vitiligo programs — Ongoing CLINUVEL-sponsored trials extending repigmentation mechanism work.

The EU label calls long-term safety data limited: no clinical study has lasted longer than 2 years, and the product is authorized under exceptional circumstances because the disease is too rare for complete information to be obtained (EU label). Observational data cover up to 8 years of use in 115 patients at two centers (Biolcati et al., 2015).

Reconstitution & Storage

The approved Scenesse product does not require reconstitution — it is a solid bioresorbable implant supplied on its own in a sealed glass vial, and the implantation cannula is not supplied with it (Scenesse label). Online guides describe research-chemical afamelanotide as a powder mixed with sterile or bacteriostatic water before injection.

• Implant storage — The labels list refrigeration at 2–8°C, the US label adds protection from light, and the implant is warmed to room temperature before insertion (Scenesse label); the EU label gives a shelf life of 4 years (EU label).
• Implant placement — By a health care professional who has completed Clinuvel’s training program, with the SFM Implantation Cannula (not supplied with the implant), under the skin 3–4 cm above the anterior supra-iliac crest; local anesthetic is optional, and the dressing stays on for 24 hours (Scenesse label).
• Research-peptide reconstitution — An online guide describes the powder being mixed with sterile or bacteriostatic water.
• Research-peptide storage — An online guide lists 2–8°C for the powder and refrigeration for the mixed solution, used within days.
• Injection sites (research-peptide) — An online guide lists the abdomen or upper arm, under the skin; practitioner reports describe rotating sites. Not equivalent to implant placement.

→ Calculator — vial-to-syringe math

Side Effects & Risks

Scenesse’s US label draws its safety data from three vehicle-controlled trials in 244 adults with EPP, 125 of whom received the implant (Scenesse label), and a long-term study followed 115 patients through 1,023 implants over up to 8 years (Biolcati et al., 2015). The EU label calls long-term safety data limited, with no clinical study longer than 2 years (EU label). The effects below come from the implant’s labels and trials; no trial has tested the research-chemical vials.

• Nausea — 19% on Scenesse vs 14% on vehicle implants in the label’s three EPP trials (Scenesse label); in the two pivotal trials, 18% vs 17% and 19% vs 18% on placebo (Langendonk et al., 2015). In the long-term study, nausea was the main adverse event attributed to afamelanotide (Biolcati et al., 2015).
• Headache — Reported by 20% of 425 patients in pooled studies, mostly mild (EU label); in the pivotal trials it was also common on placebo: 34% vs 39% in the European trial and 40% vs 29% in the US trial (Langendonk et al., 2015).
• Implant-site reaction — 21% on Scenesse vs 10% on vehicle, including bruising, discoloration, redness, bleeding, swelling, pain, itching, nodules and expelled implants; discoloration was the most common, at 10% (Scenesse label). The label describes removing the implant when clinically necessary, as after a serious allergic reaction, and notes that it may not be found from 10 days after insertion, as it resorbs (Scenesse label).
• Flushing / facial warmth — The EU label lists flushing and hot flushes as common, in 1 to 10 of every 100 patients (EU label).
• Fatigue — 6% on Scenesse vs 3% on vehicle (Scenesse label). The EU label warns that somnolence, fatigue, dizziness and nausea can affect driving, especially within 72 hours of an implant (EU label).
• Skin hyperpigmentation (intended on-target effect) — Generalized darkening of the skin and of pre-existing moles and freckles, which the label attributes to the drug’s pharmacologic effect; it was reported as an adverse reaction in 4% vs 0% on vehicle (Scenesse label). The EU label lists nail pigmentation as uncommon (EU label).
• New or changing nevi — Afamelanotide can darken pre-existing nevi, and melanocytic nevus was reported in 4% vs 2% on vehicle (Scenesse label); in the pivotal trials, moles darkened in a few patients (Langendonk et al., 2015). The Scenesse label recommends a full body skin examination twice yearly to monitor pre-existing and new skin pigmentary lesions.
• Melanoma risk — Carcinogenicity studies have not been conducted (Scenesse label). In the pivotal trials, the only melanoma reported was in a placebo patient (Langendonk et al., 2015), and a review reports no late effects in volunteers 25 years after first exposure (Minder et al., 2017). Neither label makes a history of melanoma or other skin cancer a contraindication; the EU label calls for special caution in people with a personal or family history of melanoma or a history of other skin cancers, and says its twice-yearly skin examinations are meant to catch skin cancers early (EU label).
• Sore throat, cough, dizziness, respiratory tract infection — Oropharyngeal pain 7% vs 5%, cough 6% vs 3%, dizziness 4% vs 3% and respiratory tract infection 4% vs 3%, on Scenesse vs vehicle (Scenesse label).
• Allergic reaction / hypersensitivity — Hypersensitivity reactions, including urticaria, angioedema and anaphylaxis, have been reported since approval, and a history of a severe hypersensitivity reaction to afamelanotide or its ingredients is the US label’s one contraindication (Scenesse label). The EU label calls these reactions uncommon (EU label).
• Pregnancy and lactation — The US label has no data in pregnant women or on breast milk; in rats, doses up to 12 times the maximum human dose caused no developmental harm (Scenesse label). The EU label says not to use it during pregnancy or breastfeeding, and calls for effective contraception during treatment and for three months after (EU label).
• Hepatic and renal impairment — The effect of hepatic or renal impairment on afamelanotide levels is unknown, and its metabolism has not been fully characterized (Scenesse label); the EU label lists severe hepatic disease, hepatic impairment and renal impairment as contraindications (EU label).
• Drug interactions — No interaction studies have been done (Scenesse label). The EU label notes that people taking anticoagulants such as warfarin, aspirin or NSAIDs may bruise or bleed more at the implant site (EU label).
• Research-chemical vials — The label’s safety data come from implant trials (Scenesse label); no trial has tested the vials sold for injection, and FDA has not reviewed them for identity, purity or sterility.

Bloodwork & Monitoring

Scenesse has no REMS, and its US label sets no laboratory monitoring. What the labels describe:

• Full body skin examination — The label recommends one twice yearly to monitor pre-existing and new skin pigmentary lesions, because afamelanotide can increase skin pigmentation and darken pre-existing nevi and ephelides.
• After each implant — The label has the patient observed for 30 minutes after the implant is placed, and patients asked to watch the insertion site and report any reaction (Scenesse label).
• Vital signs, blood counts and chemistry — The EU label calls for these after each implant only in patients treated despite clinically significant gastrointestinal, cardiovascular, respiratory, endocrine, neurological or blood disorders, which were not studied, and in patients over 70 (EU label).
• Injected research-chemical afamelanotide — No trial, label or guideline sets monitoring for it; the labels cover the implant only.

Commonly Stacked With

The labels describe no drug combination for EPP (Scenesse label; EU label). One combination has been tested in a trial, and both labels pair the implant with sun protection:

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching Melanotan I often also look at these:

Next Steps

References

1. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. PMID: 26132941. DOI: 10.1056/NEJMoa1411481.
2. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. PMID: 25494545.
3. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815-823. PMID: 28063031.
4. Böhm M, Wolff I, Scholzen TE, Robinson SJ, Healy E, Luger TA, Schwarz T, Schwarz A. Alpha-melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005;280(7):5795-5802. PMID: 15569680.
5. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes — a shift in paradigm. Photochem Photobiol. 2008;84(2):501-508. PMID: 18282187.
6. Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42-50. PMID: 25230094.
7. Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149(1):68-73. PMID: 23407924.
8. FDA. SCENESSE (afamelanotide) implant, prescribing information. NDA 210797, approved October 8, 2019. DailyMed, SPL version 11, published May 13, 2026 (setid 94f53286-11dd-7fbb-e053-2a95a90a7c48).
9. FDA. NDA 210797 approval letter to Clinuvel Inc., October 8, 2019. accessdata.fda.gov/drugsatfda_docs/appletter/2019/210797Orig1s000ltr.pdf.
10. European Medicines Agency. Scenesse (afamelanotide) summary of product characteristics. EMA approval December 2014 (EU/1/14/969).
11. Hadley ME, Hruby VJ. Discovery and development of novel melanogenic drugs: melanotan-I and -II. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical Biotechnology. 1992;1st ed.
12. Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC, Ertl GA, Toth K, McGee DL, Hruby VJ. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730-2736. PMID: 1658407.
13. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 1996;137(5):1627-1633. PMID: 8612494.
14. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle⁴,D-Phe⁷]-α-MSH. Br J Dermatol. 2011;164(2):407-414. PMID: 20969564.
15. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626. PMID: 26488693. (Complementary photoprotection reference.)
16. CLINUVEL Pharmaceuticals. CUV801 acute arterial ischaemic stroke proof-of-concept — Phase II proof-of-concept study of afamelanotide in acute arterial ischaemic stroke. ClinicalTrials.gov NCT04962503.
17. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, Cervino A, Zhao ZZ, Deloukas P, Soranzo N, Elder DE, Barrett JH, Martin NG, Bishop DT, Montgomery GW, Spector TD. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet. 2009;41(8):915-919. PMID: 19578365.
18. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet. 1995;11(3):328-330. PMID: 7581459.
19. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
20. CLINUVEL Pharmaceuticals. CUV102 — proof-of-concept study of afamelanotide implants and narrow-band UVB light versus NB-UVB light alone in nonsegmental vitiligo. ClinicalTrials.gov NCT01430195. Read October 4, 2026.
21. CLINUVEL Europe. CUV156 and CUV152 — Phase IIa open-label studies of afamelanotide implants in xeroderma pigmentosum. ClinicalTrials.gov NCT05159752 and NCT05370235. Read October 4, 2026.
22. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S0, Non-approved substances. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Read October 3, 2026.

Related Research

• AHK-CuCopper Tripeptide (Hair)
• ArgirelineSNAP-25 Mimetic
• Decapeptide-12Tyrosinase Inhibitor
• GHK BasicMatrikine / Cosmetic Signaling Peptide
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.